{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:33:07Z","timestamp":1790015587178,"version":"4.0.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s41669-024-00488-5","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T12:01:41Z","timestamp":1716465701000},"page":"539-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5941-6823","authenticated-orcid":false,"given":"G\u00e9rard","family":"de Pouvourville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-4238","authenticated-orcid":false,"given":"Manon","family":"Breau-Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6397-7922","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Loncle-Provot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2022-9190","authenticated-orcid":false,"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-4311","authenticated-orcid":false,"given":"Lo\u00efg","family":"Gaugain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-0723","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Nachbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-0572","authenticated-orcid":false,"given":"C\u00e9line","family":"Pribil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"19","key":"488_CR1","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","volume":"34","author":"H Lecocq","year":"2016","unstructured":"Lecocq H, Parent de Chatelet I, Taha MK, et al. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.020.","journal-title":"Vaccine"},{"issue":"9","key":"488_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/s1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. The Lancet Neurology. 2012;11(9):774\u201383. https:\/\/doi.org\/10.1016\/s1474-4422(12)70180-1.","journal-title":"The Lancet Neurology."},{"issue":"1","key":"488_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","volume":"22","author":"J Shen","year":"2022","unstructured":"Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application\u2014a systematic and clinical review. BMC Public Health. 2022;22(1):1078. https:\/\/doi.org\/10.1186\/s12889-022-13342-2.","journal-title":"BMC Public Health"},{"key":"488_CR4","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease: annual epidemiological report for 2017. Stockholm. 2019. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf. Accessed 8 Nov 2022."},{"issue":"12","key":"488_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361. https:\/\/doi.org\/10.1016\/s1473-3099(10)70251-6.","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"488_CR6","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","volume":"24","author":"MP Girard","year":"2006","unstructured":"Girard MP, Preziosi MP, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24(22):4692\u2013700. https:\/\/doi.org\/10.1016\/j.vaccine.2006.03.034.","journal-title":"Vaccine"},{"issue":"9580","key":"488_CR7","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196\u2013210. https:\/\/doi.org\/10.1016\/S0140-6736(07)61016-2.","journal-title":"Lancet"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","volume":"799","author":"NG Rouphael","year":"2012","unstructured":"Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1\u201320. https:\/\/doi.org\/10.1007\/978-1-61779-346-2_1.","journal-title":"Methods Mol Biol"},{"key":"488_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10050907","author":"AE Deghmane","year":"2022","unstructured":"Deghmane AE, Taha MK. Changes in invasive Neisseria meningitidis and Haemophilus influenzae infections in France during the COVID-19 pandemic. Microorganisms. 2022. https:\/\/doi.org\/10.3390\/microorganisms10050907.","journal-title":"Microorganisms."},{"key":"488_CR10","unstructured":"Sant\u00e9 Publique France (SPF). Invasive meningococcal infections in France in2017 [Les infections invasives \u00e0 m\u00e9ningocoque en France en 2017]. 2017. Available from: http:\/\/invs.santepubliquefrance.fr\/content\/download\/148831\/541618\/version\/4\/file\/Bilan_IIM_2017.pdf. Accessed 24 Jun 2022."},{"key":"488_CR11","unstructured":"Sant\u00e9 publique France (SPF). Invasive meningococcal infections in France in 2022 [Les infections invasives a meningocoque en France en 2022]. 2023. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/infections-invasives-a-meningocoque-en-france-en-2022. Accessed 14 Apr 2023."},{"issue":"3","key":"488_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40121-021-00468-w","volume":"10","author":"C Weil-Olivier","year":"2021","unstructured":"Weil-Olivier C, Taha MK, Emery C, et al. Healthcare resource consumption and cost of invasive meningococcal disease in France: a study of the National Health Insurance Database. Infect Dis Ther. 2021;10(3):1607\u201323. https:\/\/doi.org\/10.1007\/s40121-021-00468-w.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"488_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jiph.2015.10.016","volume":"9","author":"S B\u00e9nard","year":"2016","unstructured":"B\u00e9nard S, Wright C, Voisine J, et al. Lifetime cost of meningococcal disease in France: scenarios of severe meningitis and septicemia with purpura fulminans. J Infect Public Health. 2016;9(3):339\u201347. https:\/\/doi.org\/10.1016\/j.jiph.2015.10.016.","journal-title":"J Infect Public Health"},{"key":"488_CR14","unstructured":"Vidal. Vaccines against meningococcal meningitis [Les vaccins contre les m\u00e9ningites \u00e0 m\u00e9ningocoques]. 2022. Available from: https:\/\/www.vidal.fr\/medicaments\/utilisation\/vaccins\/vaccin-meningite-meningocoque.html. Accessed 1 Dec 2022."},{"issue":"10061","key":"488_CR15","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","volume":"388","author":"SR Parikh","year":"2016","unstructured":"Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(16)31921-3.","journal-title":"Lancet"},{"issue":"47","key":"488_CR16","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1016\/j.vaccine.2020.09.050","volume":"38","author":"A Biolchi","year":"2020","unstructured":"Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.050.","journal-title":"Vaccine"},{"issue":"5","key":"488_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2206433","volume":"388","author":"J Castilla","year":"2023","unstructured":"Castilla J, Garc\u00eda Cenoz M, Abad R, et al. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children. N Engl J Med. 2023;388(5):427\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2206433. (PMID: 36724329).","journal-title":"N Engl J Med"},{"issue":"7","key":"488_CR18","doi-asserted-by":"publisher","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","volume":"73","author":"SN Ladhani","year":"2021","unstructured":"Ladhani SN, Campbell H, Andrews N, et al. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced national surveillance, England. Clin Infect Dis. 2021;73(7):e1661\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa1244.","journal-title":"Clin Infect Dis"},{"key":"488_CR19","unstructured":"European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler: European Centre for Disease Prevention and Control (ECDC). 2022. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1. Accessed 13 Nov 2022."},{"key":"488_CR20","unstructured":"European Centre for Disease Prevention and Control (ECDC). Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU\/EEA. Stockholm. 2017. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/expert-opinion-introduction-meningococcal-b-4cmenb-vaccine-eueea. Accessed 13 Nov 2022."},{"key":"488_CR21","unstructured":"Haut Conseil de Sante Publique (HCSP). Cost-effectiveness analysis of Bexsero\u00ae vaccine for serogroup B invasive meningococcal diseases (IMD B) [Analyse co\u00fbt\/efficacit\u00e9 de la vaccination par le vaccin Bexsero\u00ae contre les infections invasives \u00e0 m\u00e9ningocoque de s\u00e9rogroupe B (IIM B)]. 2013. Available from: https:\/\/www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspr20131025_vaccmeningocoqueBBexseroann1.pdf Accessed 16 Dec 2022."},{"key":"488_CR22","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Vaccination strategy for the prevention of invasive meningococcal diseases: Serogroup B and the place of BEXSERO\u00ae [Strat\u00e9gie de vaccination pour la pr\u00e9vention des infections invasives \u00e0 m\u00e9ningocoques : Le s\u00e9rogroupe B et la place de BEXSERO\u00ae]. 2021. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3066921\/fr\/strategie-de-vaccination-pour-la-prevention-des-infections-invasives-a-meningocoques-le-serogroupe-b-et-la-place-de-bexsero. Accessed 1 Dec 2022."},{"key":"488_CR23","unstructured":"Rodrigues F, Marlow R, Simoes MJ, et al. Protocol summary: case-control study to evaluate the effectiveness of 4CMenB vaccine in the prevention of invasive meningococcal disease in Portugal. 2019. European Meningococcal and haemophilus Disease Society (EMGM). Lisbon, Portugal. Available from: https:\/\/emgm.eu\/meetings\/emgm2019\/emgm2019_abstracts.pdf. Accessed 01 Dec 2022"},{"issue":"1","key":"488_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: A comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91\u2013104. https:\/\/doi.org\/10.1016\/j.jval.2020.09.004.","journal-title":"Value Health."},{"issue":"47","key":"488_CR25","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","volume":"38","author":"E Beck","year":"2020","unstructured":"Beck E, Klint J, Garcia S, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38(47):7558\u201368. https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.007.","journal-title":"Vaccine"},{"issue":"7","key":"488_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133203","volume":"10","author":"G B\u00e9raud","year":"2015","unstructured":"B\u00e9raud G, Kazmercziak S, Beutels P, et al. The French connection: the first large population-based contact survey in France relevant for the spread of infectious diseases. PloS ONE. 2015;10(7):e0133203.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0133203.","journal-title":"PloS ONE"},{"key":"488_CR27","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Methodological choices for economic evaluation - HAS [Choix m\u00e9thodologiques pour l'\u00e9valuation \u00e9conomique \u00e0 la HAS]. Saint-Denis la Plaine. 2020. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-07\/guide_methodologique_evaluation_economique_has_2020_vf.pdf. Accessed 24 Jun 2022."},{"key":"488_CR28","doi-asserted-by":"publisher","first-page":"g5725","DOI":"10.1136\/bmj.g5725","volume":"349","author":"H Christensen","year":"2014","unstructured":"Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725. https:\/\/doi.org\/10.1136\/bmj.g5725.","journal-title":"BMJ"},{"issue":"29","key":"488_CR29","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero((R)) to reduce meningococcal group B disease in Germany. Vaccine. 2016;34(29):3412\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004.","journal-title":"Vaccine"},{"issue":"9","key":"488_CR30","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1017\/S095026881300294X","volume":"142","author":"J Huels","year":"2014","unstructured":"Huels J, Clements K, McGarry L, et al. Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. Epidemiol Infect. 2014;142(9):2000\u201312.\u00a0https:\/\/doi.org\/10.1017\/S095026881300294X.","journal-title":"Epidemiol Infect"},{"key":"488_CR31","unstructured":"R core team. R: a language and environment for statistical computing [Computer software]. 2020. Vienna, Austria. Available from: www.R-project.org."},{"key":"488_CR32","unstructured":"BERT. Basic Excel R Toolkit [Computer software]. 2018. San Francisco, California, USA. Available from: https:\/\/bert-toolkit.com\/."},{"key":"488_CR33","unstructured":"Institut National de la Statistique et des Etudes Economiques (INSEE). Tables of the French economy [Tableau de l\u2019\u00e9conomie fran\u00e7aise]. 2020 Edition, France: Institut National de la Statistique et des Etudes Economiques (INSEE). 2020. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/4277619?sommaire=4318291. Accessed 24 Jun 2022."},{"key":"488_CR34","unstructured":"Institut National d'Etudes D\u00e9mographiques (INED). Mortality rates by sex and age in 2020 [Taux de mortalit\u00e9 par sexe et \u00e2ge en 2020]. France. 2022. Available from: https:\/\/www.ined.fr\/fr\/tout-savoir-population\/chiffres\/france\/mortalite-cause-deces\/taux-mortalite-sexe-age\/. Accessed 16 Jul 2022."},{"key":"488_CR35","unstructured":"Institut National de la Statistique et des Etudes Economiques (INSEE). Population projections 2013-2070 for France [Projections de population 2013-2070 pour la France]. France. 2016. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/2496793. Accessed 16 Dec 2022."},{"key":"488_CR36","unstructured":"Berger F, Parent du Ch\u00e2telet I, Bernillon P, et al. Surveillance of the invasive meningococcal infections in France in 2005: Quantitative evaluation by the three sources capture-recapture method [Surveillance des infections invasives \u00e0 m\u00e9ningocoque en France m\u00e9tropolitaine en 2005 \u2013 \u00c9valuation quantitative par la m\u00e9thode de capture-recapture \u00e0 trois sources]. Sanitaire Idv, editor. Saint-Maurice, FR. 2010. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/rapport-synthese\/surveillance-des-infections-invasives-a-meningocoque-en-france-metropolitaine-en-2005.-evaluation-quantitative-par-la-methode-de-capture-recapture. Accessed 24 Jun 2022"},{"key":"488_CR37","unstructured":"Sant\u00e9 Publique France (SPF). Invasive meningococcal infections in France in 2019 [Les infections invasives \u00e0 m\u00e9ningocoque en France en 2019]. 2020. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/les-infections-invasives-a-meningocoque-en-france-en-2019. Accessed 24 Jun 2022."},{"issue":"1","key":"488_CR38","doi-asserted-by":"publisher","first-page":"2021764","DOI":"10.1080\/21645515.2021.2021764","volume":"18","author":"C Weil-Olivier","year":"2022","unstructured":"Weil-Olivier C, Taha MK, Bouee S, et al. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2022;18(1):2021764. https:\/\/doi.org\/10.1080\/21645515.2021.2021764.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"488_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.medmal.2018.10.004","volume":"49","author":"R Cohen","year":"2019","unstructured":"Cohen R, Gaudelus J, Leboucher B, et al. Impact of mandatory vaccination extension on infant vaccine coverages: Promising preliminary results. Med Mal Infect. 2019;49(1):34\u20137. https:\/\/doi.org\/10.1016\/j.medmal.2018.10.004.","journal-title":"Med Mal Infect."},{"issue":"6","key":"488_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","volume":"2","author":"P Bryan","year":"2018","unstructured":"Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395\u2013403. https:\/\/doi.org\/10.1016\/S2352-4642(18)30103-2.","journal-title":"Lancet Child Adolesc Health."},{"key":"488_CR41","unstructured":"Public Health England (PHE). Progress report on 4CMenB (Bexsero) vaccine coverage and effectiveness in England. In: Third annual report 01 September 2015\u201331 August 2018. 2018."},{"issue":"3","key":"488_CR42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jinf.2017.12.005","volume":"76","author":"F Martin\u00f3n-Torres","year":"2018","unstructured":"Martin\u00f3n-Torres F, Martinez AC, Simk\u00f3 R, et al. Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. J Infect. 2018;76(3):258\u201369. https:\/\/doi.org\/10.1016\/j.jinf.2017.12.005.","journal-title":"J Infect"},{"key":"488_CR43","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9vention. Third annual review of compulsory infant vaccinations [Troisi\u00e8me bilan annuel des obligations vaccinales du nourrisson] Paris. 2022. Available from: https:\/\/sante.gouv.fr\/IMG\/pdf\/bilan_3eme_annee_obligations_vaccinales.pdf. Accessed 31 Jan 2024."},{"issue":"5","key":"488_CR44","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.4161\/hv.23888","volume":"9","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Hak E, van der Ende A, et al. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence.\u00a0Hum Vaccin Immunother. 2013;9(5):1129\u201338. https:\/\/doi.org\/10.4161\/hv.23888","journal-title":"Hum Vaccin Immunother."},{"issue":"23","key":"488_CR45","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","volume":"31","author":"H Christensen","year":"2013","unstructured":"Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31(23):2638\u201346. https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.034.","journal-title":"Vaccine"},{"issue":"6","key":"488_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00038-016-0821-0","volume":"61","author":"GM Ginsberg","year":"2016","unstructured":"Ginsberg GM, Block C, Stein-Zamir C. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel. Int J Public Health. 2016;61(6):683\u201392. https:\/\/doi.org\/10.1007\/s00038-016-0821-0.","journal-title":"Int J Public Health"},{"issue":"2","key":"488_CR47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, et al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205\u201316. https:\/\/doi.org\/10.1007\/s10198-018-0955-5.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"488_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177082","volume":"12","author":"ITR Kennedy","year":"2017","unstructured":"Kennedy ITR, van Hoek AJ, Ribeiro S, et al. Short-term changes in the health state of children with group B meningococcal disease: a prospective, national cohort study. PLoS ONE. 2017;12(5): e0177082. https:\/\/doi.org\/10.1371\/journal.pone.0177082.","journal-title":"PLoS ONE"},{"issue":"12","key":"488_CR49","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529\u201344. https:\/\/doi.org\/10.1002\/hec.3259.","journal-title":"Health Econ"},{"issue":"3","key":"488_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","volume":"59","author":"J Song","year":"2010","unstructured":"Song J, Floyd FJ, Seltzer MM, et al. Long-term effects of child death on parents\u2019 health related quality of life: a dyadic analysis. Fam Relat. 2010;59(3):269\u201382. https:\/\/doi.org\/10.1111\/j.1741-3729.2010.00601.x.","journal-title":"Fam Relat"},{"issue":"5","key":"488_CR51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, et al. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737\u20139. https:\/\/doi.org\/10.1086\/322587.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"488_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/bjo.85.3.327","volume":"85","author":"MM Brown","year":"2001","unstructured":"Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327\u201331. https:\/\/doi.org\/10.1136\/bjo.85.3.327.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"488_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","volume":"55","author":"R Oostenbrink","year":"2002","unstructured":"Oostenbrink R, Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791\u20139.\u00a0https:\/\/doi.org\/10.1016\/S0895-4356(02)00448-1","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"488_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001307","volume":"9","author":"M Wyld","year":"2012","unstructured":"Wyld M, Morton RL, Hayen A, et al. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9): e1001307. https:\/\/doi.org\/10.1371\/journal.pmed.1001307.","journal-title":"PLoS Med"},{"issue":"4","key":"488_CR55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00005373-199804000-00011","volume":"44","author":"P Blakeney","year":"1998","unstructured":"Blakeney P, Meyer W 3rd, Robert R, et al. Long-term psychosocial adaptation of children who survive burns involving 80% or greater total body surface area. J Trauma. 1998;44(4):625\u201332 (discussion 633-4). https:\/\/doi.org\/10.1097\/00005373-199804000-00011","journal-title":"J Trauma"},{"issue":"4","key":"488_CR56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1192\/bjp.bp.106.025106","volume":"190","author":"SI Saarni","year":"2007","unstructured":"Saarni SI, Suvisaari J, Sintonen H, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry. 2007;190(4):326\u201332. https:\/\/doi.org\/10.1192\/bjp.bp.106.025106.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"488_CR57","first-page":"43","volume":"154","author":"JE Bennett","year":"2000","unstructured":"Bennett JE, Sumner W 2nd, Downs SM, et al. Parents\u2019 utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43\u20138. https:\/\/doi.org\/10-1001\/pubs.Pediatr Adolesc Med.-ISSN-1072-4710-154-1-poa9043. (PMID: 10632249)","journal-title":"Arch Pediatr Adolesc Med"},{"key":"488_CR58","unstructured":"Ameli. Drug database and pricing information [Base des M\u00e9dicaments et Informations Tarifaires]. 2019. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index_presentation.php?p_site=AMELI Accessed 15 May 2022."},{"key":"488_CR59","unstructured":"Institut National de la Statistique et des Etudes Economiques (INSEE). Consumer price index - Base 2015 - All households - France - Health services - Identifier 001763845 [Indice des prix \u00e0 la consommation - Base 2015 - Ensemble des m\u00e9nages - France - Services de sant\u00e9 - Identifiant 001763845]. 2019. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001763845#Telechargement. Accessed 24 Jun 2022."},{"issue":"5","key":"488_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026953","volume":"9","author":"JG Zafack","year":"2019","unstructured":"Zafack JG, Bureau A, Skowronski DM, et al. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open. 2019;9(5):e026953. https:\/\/doi.org\/10.1136\/bmjopen-2018-026953.","journal-title":"BMJ Open"},{"issue":"9869","key":"488_CR61","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(12)61961-8. (PMID: 23324563).","journal-title":"Lancet"},{"issue":"28","key":"488_CR62","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","volume":"35","author":"F Martinon-Torres","year":"2017","unstructured":"Martinon-Torres F, Safadi MAP, Martinez AC, et al. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. Vaccine. 2017;35(28):3548\u201357. https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.023.","journal-title":"Vaccine"},{"issue":"6","key":"488_CR63","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape M, Yu L, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573\u201382. https:\/\/doi.org\/10.1001\/jama.2012.85.","journal-title":"JAMA"},{"key":"488_CR64","unstructured":"Service Public fran\u00e7ais. Reimbursement of a medical consultation for a child under 16 years old [Remboursement d'une consultation m\u00e9dicale pour un enfant de moins de16 ans]. 2021. Available from: https:\/\/www.service-public.fr\/particuliers\/vosdroits\/F10874 Accessed 24 Jun 2022."},{"issue":"10","key":"488_CR65","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/archdischild-2017-312941","volume":"102","author":"V Nainani","year":"2017","unstructured":"Nainani V, Galal U, Buttery J, et al. An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study. Arch Dis Child. 2017;102(10):958\u201362. https:\/\/doi.org\/10.1136\/archdischild-2017-312941","journal-title":"Arch Dis Child"},{"key":"488_CR66","unstructured":"Service Public Fran\u00e7ais. Education allowance for disabled children [Allocation d\u2019\u00e9ducation de l\u2019enfant handicap\u00e9 (AEEH)]. 2019. Available from: https:\/\/www.service-public.fr\/particuliers\/vosdroits\/F14809. Accessed 15 May 2022."},{"key":"488_CR67","unstructured":"Caisse Allocations Familiales (CAF). Education allowance for disabled children [Allocation d\u2019\u00e9ducation de l\u2019enfant handicap\u00e9 (AEEH)]. 2019. Available from: http:\/\/data.caf.fr\/dataset\/foyers-allocataires-percevant-l-allocation-d-education-de-l-enfant-handicape-aeeh-par-caf Accessed 15 May 2022."},{"key":"488_CR68","unstructured":"Direction de la Recherche des Etudes de l'Evaluation et des Statistiques (DREES). Beneficiaries of departmental social assistance for the elderly or disabled (APA, PCH, ASH, Household help, etc.) [Les b\u00e9n\u00e9ficiaires de l'aide sociale d\u00e9partementale aux personnes \u00e2g\u00e9es ou handicap\u00e9es (APA, PCH, ASH, Aides m\u00e9nag\u00e8res, \u2026)]. 2022. Available from: https:\/\/data.drees.solidarites-sante.gouv.fr\/explore\/dataset\/les-beneficiaires-de-l-aide-sociale-departementale-aux-personnes-agees-ou-handic\/information\/. Accessed 24 Jun 2022."},{"key":"488_CR69","unstructured":"Direction de la Recherche des Etudes de l'Evaluation et des Statistiques (DREES). Disability compensation benefit (PCH) and compensation allowance for third person (ACTP) [La prestation de compensation du handicap (PCH) et l\u2019allocation compensatrice pour tierce personne (ACTP)]. 2020. Available from: https:\/\/drees.solidarites-sante.gouv.fr\/prestation-de-compensation-du-handicap-pch-et-allocation-compensatrice-pour-tierce-personne-actp. Accessed 24 Jun 2022."},{"key":"488_CR70","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. INSTRUCTION No. DGS\/SP\/2018\/163 of July 27, 2018 relating to prophylaxis invasive meningococcal infections [INSTRUCTION N\u00b0 DGS\/SP\/2018\/163 du 27 juillet 2018 relative \u00e0 la prophylaxie des infections invasives \u00e0 m\u00e9ningocoque]. 2018. Available from: https:\/\/sante.gouv.fr\/IMG\/pdf\/instruction_dgs_sp_2018_163.pdf. Accessed 7 Sep 2023."},{"key":"488_CR71","first-page":"620","volume":"30\u201331","author":"D Dejour Salamanca","year":"2018","unstructured":"Dejour Salamanca D, Tararbit K, Pr\u00e9vosto F, et al. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais (Rh\u00f4ne, France) 2016:\u00a0organization of the immunization campaign and results [Epid\u00e9mie d\u2019infections invasives \u00e0 m\u00e9ningocoque B dans le Beaujolais (Rh\u00f4ne), 2016: organisation de la vaccination et r\u00e9sultats]. Bull Epid\u00e9miol Hebdo. 2018;30\u201331:620\u20137.","journal-title":"Bull Epid\u00e9miol Hebdo"},{"key":"488_CR72","unstructured":"Agence R\u00e9gionale de Sant\u00e9 (ARS) Bourgogne-Franche-Comt\u00e9. Exceptional vaccination campaign on campus of Dijon: First assessment [Campagne de vaccination exceptionnelle sur le campus de Dijon : premier bilan]. 2017. Available from: http:\/\/www.prefectures-regions.gouv.fr\/bourgogne-franche-comte\/content\/download\/30803\/210379\/file\/20170214_bilan_campagne_vaccination.pdf. Accessed 15 May 2022."},{"key":"488_CR73","unstructured":"Agence r\u00e9gionale de Sant\u00e9 (ARS) Bourgogne-Franche-Comt\u00e9. Meningococcal W vaccination [Vaccination contre le m\u00e9ningocoque W]. 2019. Available from: https:\/\/www.bourgogne-franche-comte.ars.sante.fr\/vaccination-contre-le-meningocoque-w. Accessed 15 May 2022."},{"issue":"2\u20133","key":"488_CR74","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.healthpol.2014.02.009","volume":"116","author":"E Nord","year":"2014","unstructured":"Nord E, Johansen R. Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY. Health Policy. 2014;116(2\u20133):281\u20138. https:\/\/doi.org\/10.1016\/j.healthpol.2014.02.009.","journal-title":"Health Policy"},{"issue":"9960","key":"488_CR75","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. The Lancet. 2014;384(9960):2123\u201331.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(14)60842-4","journal-title":"The Lancet"},{"issue":"1","key":"488_CR76","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40121-021-00546-z","volume":"11","author":"J Shen","year":"2022","unstructured":"Shen J, Bouee S, Aris E, et al. Long-term mortality and state financial support in invasive meningococcal disease-real-world data analysis using the French National Claims Database (SNIIRAM). Infect Dis Ther. 2022;11(1):249\u201362. https:\/\/doi.org\/10.1007\/s40121-021-00546-z.","journal-title":"Infect Dis Ther"},{"key":"488_CR77","unstructured":"Institute for Clinical and Economic Review (ICER). ICER 2019 Perspectives on Cost-Effectiveness Threshold Ranges. 2019. Available from: https:\/\/icer.org\/wp-content\/uploads\/2023\/08\/ICER_2019_Perspectives-on-Cost-Effectiveness-Threshold-Ranges.pdf. Accessed 8 Feb 2024."},{"key":"488_CR78","volume-title":"Health technology assessment (HTA)","author":"G Hanquet","year":"2014","unstructured":"Hanquet G, Christensen H, Trotter C, et al. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study. In: (KCE) BHCKC, editor., et al., Health technology assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2014."},{"issue":"7","key":"488_CR79","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745\u201358. https:\/\/doi.org\/10.1007\/s40273-018-0672-z.","journal-title":"Pharmacoeconomics"},{"key":"488_CR80","unstructured":"Medicines Australia. Submission to the PBAC on the Base Case Discount Rate. 2022. Available from: https:\/\/www.biointelect.com\/submission-to-the-pbac-on-the-base-case-discount-rate\/. Accessed 16 Apr 2024"},{"issue":"1","key":"488_CR81","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jval.2020.09.005","volume":"24","author":"L Annemans","year":"2021","unstructured":"Annemans L, Beutels P, Bloom DE, et al. Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. Value Health. 2021;24(1):105\u201311. https:\/\/doi.org\/10.1016\/j.jval.2020.09.005.","journal-title":"Value Health."},{"issue":"3","key":"488_CR82","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","volume":"34","author":"B Ultsch","year":"2016","unstructured":"Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European Vaccine Economics Community. Pharmacoeconomics. 2016;34(3):227\u201344. https:\/\/doi.org\/10.1007\/s40273-015-0335-2.","journal-title":"Pharmacoeconomics"},{"key":"488_CR83","unstructured":"Haut Conseil de Sant\u00e9 Publique (HCSP). Vaccination with meningococcal serogroup C conjugate vaccine [Vaccination par le vaccin conjugu\u00e9 contre le m\u00e9ningocoque de s\u00e9rogroupe C]. 2009. Available from: https:\/\/www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspr20090424_meningC.pdf. Accessed 24 Jun 2022."},{"key":"488_CR84","unstructured":"Joint Committee on Vaccination and Immunisation (JCVI). Minutes of the meeting on 11 and 12 February 2014. 2014. Available from: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/229171703722. Accessed 15 May 2022."},{"key":"488_CR85","unstructured":"Rodrigues F, Marlow R, Simoes MJ, et al. Protocol Summary : case-control study to evaluate the effectiveness of 4CMenB vaccine in the prevention of invasive meningococcal disease in Portugal\u2014(EMGM 2019- 13358). 2019. 15th European Meningococcal and haemophilus Disease Society (EMGM) Congress. Lisbon, Portugal."},{"key":"488_CR86","unstructured":"INFOVAC-FRANCE. Invasive meningococcal infections [Infections invasives \u00e0 M\u00e9ningocoque ], Bulletin 2. 2023. Available from: https:\/\/www.infovac.fr\/actualites\/bulletin-n-2-fevrier-2023. Accessed 8 Feb 2023."},{"issue":"1","key":"488_CR87","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, et al. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup B invasive meningococcal disease. Infect Dis Therapy. 2022;11(1):367\u201387. https:\/\/doi.org\/10.1007\/s40121-021-00573-w.","journal-title":"Infect Dis Therapy"},{"issue":"12","key":"488_CR88","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1080\/21645515.2019.1627159","volume":"15","author":"F Martinon-Torres","year":"2019","unstructured":"Martinon-Torres F, Nolan T, Toneatto D, et al. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother. 2019;15(12):2940\u201351. https:\/\/doi.org\/10.1080\/21645515.2019.1627159.","journal-title":"Hum Vaccin Immunother"},{"key":"488_CR89","unstructured":"Huang L, Balmer P, Farkouh R. Can current health economic modeling frameworks capture the unpredictability of invasive meningococcal disease? 2019. Meningitis Research Conference (MRC). London, UK. Available from: https:\/\/www.meningitis.org\/getmedia\/621715fb-bfde-4a1a-8a26-985e7c9cd954\/All-Poster-Abstracts-2019_final?disposition=attachment. Accessed 16 Apr 2024."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00488-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00488-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00488-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T07:02:41Z","timestamp":1721113361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00488-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00488-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"20 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a non-interventional study without the participation of human subjects. No ethics approval was required. The study only used anonymized patient data and was compliant with procedures outlined by the National Commission on Informatics and Liberty (<i>Commission Nationale de l'Informatique et des Libert\u00e9s<\/i> \u2013 <i>CNIL<\/i>).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This was a non-interventional study which did not enroll patients. No informed consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"GdP received personal consulting fees from GSK for his involvement in advisory boards on health economic studies related to MenB (related to the present publication) and other vaccines. GdP also received honoraria from GSK for a press conference on MenB vaccination. MBB and LG are employees of Amaris Consulting. Amaris Consulting received financial compensation from GSK for performing the study related to this publication. VLP, EB, CP and GN are employed by and hold shares in GSK. The authors declare no other financial and non-financial relationships and activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This was a non-interventional study which did not enroll patients. No informed consent was required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO 000057) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took charge of all costs associated with the development and publication of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors participated in the design, implementation, analysis, and interpretation of the study and the development of this manuscript. All authors had full access to the data and gave final approval before submission. All authors agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributorship"}},{"value":"GSK makes available anonymized individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to . To access data for other types of GSK-sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via the website.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The invasive meningococcal disease dynamic transmission model was programmed in MS Excel 2016 and updated in Excel Office 365. The model was developed by GSK and is proprietary in nature. Further information is available upon request from the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}